Cancer stem cells (CSCs) are considered crucial drivers of tumor heterogeneity and recurrence,[4] characterized by their ability to self‐renewal capabilities, leading to tumor initiation and progression.[5] Liver CSCs are currently identified and isolated using surface markers such as CD13, CD133, CD44, CD90, and EpCAM, which are well established in research.[6] Although clinical therapies against these surface markers have been shown to alleviate tumor progression,[7, 8] the potential of nucleic acid‐based therapies to provide new insights into HCC treatment remains largely unexplored. This evidence concerns the gene EPCAM and neoplasm.